Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parkinson's disease gene therapy - Axovant Gene Therapies/Oxford BioMedica

Drug Profile

Parkinson's disease gene therapy - Axovant Gene Therapies/Oxford BioMedica

Alternative Names: AXO Lenti PD; OXB-101; OXB-102; ProSavin; Tricistronic lentiviral vector encoding for TH, AADC and CH1 - Oxford BioMedica

Latest Information Update: 23 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oxford BioMedica
  • Developer Axovant Gene Therapies; Oxford BioMedica
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Dopamine release stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Parkinson's disease

Most Recent Events

  • 08 Nov 2019 Axovant Gene Therapies plans a clinical trial for Axo Lenti PD for Parkinson's disease by the end of 2020
  • 09 Jul 2019 AXO Lenti PD is still in phase I/II trials for Parkinson's Disease in United Kingdom
  • 06 Jun 2019 Updated efficacy data from a phase I/II trial in Parkinson's disease released by Axovant
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top